[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 64 of about 64
1. Guo DH, Pang SJ, Shen Y: [Atypical endometriosis: a clinicopathologic study of 163 cases]. Zhonghua Fu Chan Ke Za Zhi; 2008 Nov;43(11):831-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathologic changes of AEM including its glandular epithelium, stroma, background and the conditions coexisting with tumor were observed.
  • AEM associated with tumour was found in 26 cases (15.95%) and among 27 of ovarian AEM, 15 were malignant, 9 borderline and 3 benign.
  • The AEM epithelia were mainly arranged in the form of surface epithelium.
  • They present with characteristic features of moderate to marked pleomorphism, epithelial tufting and bud structures by microscopy.
  • The walls of AEM cyst were presented with three layers of epithelium, endometrioid stroma and fibrosis-collagen.
  • The transformation from AEM to tumor was found in most of the malignant tumors (14/15, 93%).
  • CONCLUSIONS: AEM lesions hold some features of both EM and tumor, which may have a relatively higher potential for tumorigenesis and canceration.
  • The process of damage and repair in EM foci during a long course may play a role in the development of EM into AEM and finally into tumor.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometriosis / pathology. Epithelium / pathology. Ovarian Neoplasms / pathology


2. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res; 2005 Mar 15;65(6):2162-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the genes most commonly identified in gene expression profiles of epithelial ovarian carcinomas (EOC) is the gene for human epididymis protein 4 (HE4).
  • To ascertain its clinical utility, we did a comprehensive assessment of HE4 protein expression in benign and malignant ovarian and nonovarian tissues by immunohistochemistry.
  • In comparison with normal surface epithelium, which does not express HE4, we found that cortical inclusion cysts lined by metaplastic Mullerian epithelium abundantly express the protein.
  • Tissue microarrays revealed that the majority of nonovarian carcinomas do not express HE4, consistent with our observation that HE4 protein expression is highly restricted in normal tissue to the reproductive tracts and respiratory epithelium.
  • Its expression in cortical inclusion cysts suggests that formation of Mullerian epithelium is a prerequisite step in the development of some types of EOCs.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Epididymal Secretory Proteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Epithelium / metabolism. Female. Humans. Mullerian Ducts / metabolism. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. beta-Defensins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781627.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / RNA, Messenger; 0 / beta-Defensins
  •  go-up   go-down


3. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I, Prus D: Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem; 2010 Nov;58(11):1015-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis.
  • Here, we investigated the expression of SAA in human benign and malignant ovarian epithelial tumors.
  • Non-radioactive in situ hybridization applied on ovarian paraffin tissue sections revealed mostly negative SAA mRNA expression in normal surface epithelium.
  • Expression was increased gradually as epithelial cells progressed through benign and borderline adenomas to primary and metastatic adenocarcinomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. C-Reactive Protein / metabolism. CA-125 Antigen / blood. Cell Line, Tumor. Female. Humans. Middle Aged. Neoplasm Metastasis. Ovary / cytology. Ovary / metabolism. Ovary / pathology. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1983 Nov;43(11):5379-89 [6604576.001]
  • [Cites] Ann Intern Med. 1979 Sep;91(3):383-90 [289303.001]
  • [Cites] Scand J Immunol. 1984 Mar;19(3):193-8 [6200925.001]
  • [Cites] Biochem Biophys Res Commun. 1991 May 15;176(3):1100-5 [2039494.001]
  • [Cites] DNA Cell Biol. 1991 Nov;10(9):651-61 [1755958.001]
  • [Cites] J Biol Chem. 1992 Feb 25;267(6):3862-7 [1740433.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3186-90 [8159722.001]
  • [Cites] Genomics. 1994 Jan 15;19(2):228-35 [8188253.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):203-9 [7516407.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):650-60 [8080047.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1184-90 [7636186.001]
  • [Cites] Lab Invest. 1998 May;78(5):535-9 [9605178.001]
  • [Cites] J Histochem Cytochem. 1998 Dec;46(12):1377-84 [9815279.001]
  • [Cites] J Rheumatol. 1999 Apr;26(4):785-90 [10229397.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Eur J Immunol. 2005 Mar;35(3):718-26 [15724247.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 13;330(3):989-98 [15809093.001]
  • [Cites] Proteomics. 2005 Sep;5(14):3790-7 [16121334.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1361-9 [16211233.001]
  • [Cites] J Histochem Cytochem. 2006 Jan;54(1):63-73 [16116035.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):105-14 [16385502.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21 [16297528.001]
  • [Cites] J Immunol. 2006 Oct 15;177(8):5585-94 [17015746.001]
  • [Cites] Biomed Environ Sci. 2007 Feb;20(1):33-40 [17458139.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Apr 4;368(2):368-73 [18237545.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):579-85 [18243142.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):985-95 [18028381.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2199-208 [19307507.001]
  • [Cites] Br J Cancer. 2009 Jul 21;101(2):335-41 [19536090.001]
  • [Cites] Cancer. 2010 Feb 15;116(4):843-51 [20041483.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Jul;136(7):1079-88 [20082099.001]
  • [Cites] Eur Urol. 2010 May;57(5):859-66 [19747761.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):794-7 [3734116.001]
  • [Cites] Curr Opin Hematol. 2000 Jan;7(1):64-9 [10608507.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 16;268(2):405-8 [10679217.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):497-502 [11304683.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1224-9 [11830469.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] J Histochem Cytochem. 1984 Mar;32(3):322-8 [6363521.001]
  • (PMID = 20713982.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Serum Amyloid A Protein; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ PMC2958134
  •  go-up   go-down


Advertisement
4. Di Carlo R, Rinaldi R, Ottaviano G, Pastore A: Respiratory epithelial adenomatoid hamartoma of the maxillary sinus: case report. Acta Otorhinolaryngol Ital; 2006 Aug;26(4):225-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Respiratory epithelial adenomatoid hamartoma of the maxillary sinus: case report.
  • The case is described of a male patient with respiratory epithelial adenomatoid hamartoma of the left maxillary sinus that initially presented as a chronic sinus inflammation.
  • This benign lesion is characterized by glandular proliferation originating from the surface of the respiratory epithelium.
  • Moreover, misinterpretation of the respiratory epithelial adenomatoid hamartoma as chronic sinus inflammation may result in inadequate treatment.
  • [MeSH-major] Adenomatoid Tumor / pathology. Hamartoma / pathology. Maxillary Sinus / pathology. Paranasal Sinus Neoplasms / pathology. Respiratory Mucosa / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Aug;104(8):639-45 [7639474.001]
  • [Cites] Head Neck. 1992 Jul-Aug;14(4):321-7 [1517084.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 May;97(5):607-12 [15153874.001]
  • [Cites] Laryngorhinootologie. 2003 Jun;82(6):416-20 [12851849.001]
  • [Cites] Acta Otolaryngol. 2002 Jun;122(4):398-400 [12125996.001]
  • [Cites] J Laryngol Otol. 2002 Apr;116(4):317-8 [11945202.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 2004;125(1):45-8 [15244029.001]
  • [Cites] Otolaryngol Pol. 2005;59(3):421-4 [16117401.001]
  • [Cites] J Laryngol Otol. 2005 Jun;119(6):476-8 [15992477.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Mar;132(3):407-12; discussion 413 [15746852.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256 Suppl 1:S33-7 [10337524.001]
  • [Cites] Am J Otolaryngol. 2004 Jul-Aug;25(4):282-4 [15239039.001]
  • [Cites] Mod Pathol. 2002 Mar;15(3):279-97 [11904343.001]
  • (PMID = 18236641.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2639995
  •  go-up   go-down


5. Liu X, Ma YQ, Wang J: [Prepubertal-type vulva fibroma: a clinicopathological study of two cases]. Zhonghua Bing Li Xue Za Zhi; 2010 Jan;39(1):40-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Grossly, cut surface of the tumor appeared as the gray fibrous tissue without any definited lump detected.
  • The tumor cells extended downward under the epithelium and infiltrated between the fat tissue, nerve fibers as well as the capillaries making a lesion looked somewhat like a harmatoma.
  • CONCLUSIONS: PVF is a benign mesenchymal lesion with a predilection of involving the vulva of prepubertal girls or adults in rare cases.
  • [MeSH-minor] Antigens, CD34 / metabolism. Child. Diagnosis, Differential. Female. Humans. Middle Aged. Myxoma / pathology. Neoplasm Recurrence, Local. Vulva / pathology. Vulva / surgery

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388398.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vimentin
  •  go-up   go-down


6. Bei R, Masuelli L, Trono P, Orvietani PL, Losito S, Marzocchella L, Vitolo D, Albonici L, Mrozek MA, Di Gennaro E, Lista F, Faggioni G, Ionna F, Binaglia L, Manzari V, Budillon A, Modesti A: The ribosomal P0 protein induces a spontaneous immune response in patients with head and neck advanced stage carcinoma that is not dependent on its overexpression in carcinomas. Int J Oncol; 2007 Dec;31(6):1301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overexpression of this epitope was also significantly associated with a number of pathological lesions arising in the head and neck stratified epithelium including acanthosis (8/8), benign tumors (11/11), dysplasia (23/25) and in situ carcinomas (9/9).
  • Increased expression of the C-22 P0 epitope on the surface of pharynx cancer cells following cellular stress in vitro, may imply P0 protein presentation as an in vivo autoantibody target in cancer patients.
  • [MeSH-minor] Amino Acid Sequence. Antibodies / blood. Antibodies, Monoclonal / immunology. Cell Line, Tumor. Epitopes. Humans. Molecular Sequence Data. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982655.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Epitopes; 0 / Ribosomal Proteins; 0 / ribosomal protein P0
  •  go-up   go-down


7. Tahlan A, Nanda A, Mohan H: Uterine adenomyoma: a clinicopathologic review of 26 cases and a review of the literature. Int J Gynecol Pathol; 2006 Oct;25(4):361-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenomyoma of the uterus is a circumscribed nodular aggregate of benign endometrial glands surrounded by endometrial stroma with leiomyomatous smooth muscle bordering the endometrial stromal component.
  • The criterion used for case identification was a circumscribed mass composed of benign endometrial glands with a stromal component consisting of endometrial type stroma surrounded by leiomyomatous smooth muscle.
  • Thirteen patients underwent panhysterectomy; 7, total hysterectomy; 1, subtotal hysterectomy; 4, polypectomy or tumor removal; and 1, curettage.
  • The adenomyomas were firm in consistency and, on cut section, showed a gray-white surface.
  • The glands were lined by benign proliferative pseudostratified columnar epithelium.
  • This study highlights the importance of correctly identifying this fairly common entity and helps to distinguish adenomyoma from other similar appearing benign and malignant lesions.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990713.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


8. Mendrinos S, Nolen JD, Styblo T, Carlson G, Pohl J, Lewis M, Ritchie J: Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry. Cancer; 2005 Jun 25;105(3):178-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry.
  • The authors' work focused on an innovative technique that couples breast ductal lavage (DL) with surface-enhanced laser desorption and ionization-time of flight mass spectrometry (SELDI-TOF MS) to yield a highly sensitive and specific method of breast carcinoma detection.
  • Studying paired DL specimens from each woman (the breast with and the breast without carcinoma), a cytologic investigation was performed on the cells present in the DL samples, and the protein content of the DL fluid was analyzed with the SELDI-TOF MS technique using the strong anionic exchange chip surface.
  • RESULTS: Only 5 of 16 DL specimens (31%) from breasts with biopsy-proven carcinoma contained malignant cells, whereas the remaining samples contained only histiocytes and clusters of benign ductal epithelium.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal / pathology. Neoplasm Proteins / analysis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] BRCA1 Protein / analysis. BRCA2 Protein / analysis. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Case-Control Studies. Cytodiagnosis / methods. Female. Humans. Immunohistochemistry. Nipples / cytology. Sampling Studies. Sensitivity and Specificity. Tissue Culture Techniques

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15822128.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


9. Khunamornpong S, Lerwill MF, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Chiangmai WN, Young RH: Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol; 2008 Jul;27(3):366-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumor was identified before the detection of the ovarian lesions in 5 cases, was simultaneously detected with the ovarian metastases in 9, and was diagnosed postoperatively in 2.
  • The sectioned surface was solid in 9, solid-cystic in 15, and multicystic in 5.
  • Microscopically, ovarian surface implants were seen in 66%, multinodular growth in 58%, and infiltrative stromal invasion in 81%.
  • Mucinous epithelial differentiation was seen in 81%, sometimes with foci of benign-like or borderline-like epithelium simulating primary ovarian mucinous neoplasia.
  • Cystadenoma and cystadenofibroma of nonmucinous type was even mimicked strikingly in some cases because of flattening of epithelium lining glands and cysts.
  • Signet ring cells were present in sufficient quantity for a diagnosis of Krukenberg tumor in four tumors.
  • Nonmucinous carcinomatous components included adenocarcinoma with high-grade endometrioid-like morphology in 2 cases, papillary adenocarcinoma simulating mixed müllerian epithelial adenocarcinoma in 1, and undifferentiated carcinoma in 2.
  • The high rate of bilaterality, surface involvement, multinodular growth, and heterogeneity of patterns were the most helpful features for indicating a metastatic nature, with signet ring cells also being helpful in the minority of cases in which they were present.
  • Although the diagnosis of a metastatic tumor to the ovary is possible in most of the cases based on standard diagnostic criteria, problems in the differential diagnosis may be posed by morphologic patterns that overlap strikingly with primary ovarian neoplasms, benign, borderline, and malignant, as discussed herein.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580314.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Park CM, Goo JM, Lee HJ, Kim MA, Lee CH, Kang MJ: Tumors in the tracheobronchial tree: CT and FDG PET features. Radiographics; 2009 Jan-Feb;29(1):55-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A variety of tumors, including primary malignant tumors, secondary malignant tumors, and benign tumors, can occur in the tracheobronchial tree.
  • Primary malignant tumors commonly originate from the surface epithelium or the salivary glands, whereas most benign tumors arise from the mesenchymal tissue.
  • Carcinoid tumors commonly show intense enhancement at contrast material-enhanced CT, which can be helpful in making the diagnosis, and usually have lower uptake at FDG PET than would be expected for a malignant tumor.
  • Their CT manifestations are similar to those of primary malignant tumors, with uptake at FDG PET depending primarily on the metabolic activity and degree of differentiation of the primary tumor.
  • Among the benign tumors, hamartoma and lipoma can show characteristic CT findings such as "popcorn" calcification or internal fat.
  • However, CT findings in most benign tumors are nonspecific.
  • At FDG PET, benign tumors usually show little or no uptake and can be differentiated from malignant tumors.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • (PMID = 19168836.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


11. Khunamornpong S, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Na Chiangmai W, Young RH: Intrahepatic cholangiocarcinoma metastatic to the ovary: a report of 16 cases of an underemphasized form of secondary tumor in the ovary that may mimic primary neoplasia. Am J Surg Pathol; 2007 Dec;31(12):1788-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic cholangiocarcinoma metastatic to the ovary: a report of 16 cases of an underemphasized form of secondary tumor in the ovary that may mimic primary neoplasia.
  • Microscopically, surface implants were observed in 80% of tumors, multinodular growth in 48%, and infiltrative stromal invasion (including microinvasionlike foci as it would be applied if the tumors were primary) in 86%.
  • The neoplastic epithelium typically formed glands that ranged from small to large and cystically dilated, but small clusters of cells and individual cells were also seen.
  • The epithelium ranged from tall, columnar, and mucinous in appearance to cuboidal or flattened and nonspecific.
  • Foci often mimicked mucinous borderline tumors of typical type or with intraepithelial carcinoma and benign-appearing mucinous epithelium was seen in 62% of tumors.
  • Intrahepatic cholangiocarcinoma should be included in the list of origins of possible ovarian metastatic tumors that mimic primary ovarian mucinous neoplasia, particularly in parts of the world where cholangiocarcinoma of the liver is relatively common.


12. Wu HH, Zafar S, Huan Y, Yee H, Chiriboga L, Wang BY: Fascin over expression is associated with dysplastic changes in sinonasal inverted papillomas: a study of 47 cases. Head Neck Pathol; 2009 Sep;3(3):212-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sinonasal inverted papilloma (IP) is a primary benign lesion with a tendency for local recurrence.
  • Fascin (Fascin 1) is an actin cross-link binding protein required for the formation of actin-based cell-surface protrusions and cell motility.
  • Fascin over-expression is significantly more common in sinonasal IP with high-grade dysplasia than in those with no dysplastic or low-grade dysplastic epithelium (P = 0.0001).
  • Over expression of fascin in high-grade dysplastic epithelium in IP may be associated with tumor progression and malignant transformation.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2008 Jun;61(6):707-12 [18505889.001]
  • [Cites] Laryngoscope. 1995 Mar;105(3 Pt 1):282-8 [7877417.001]
  • [Cites] Am J Otolaryngol. 2009 Jan-Feb;30(1):38-43 [19027511.001]
  • [Cites] Arch Pathol Lab Med. 2008 Dec;132(12):1912-5 [19061289.001]
  • [Cites] Hum Pathol. 2009 Feb;40(2):174-80 [18835624.001]
  • [Cites] Acta Otolaryngol. 2009 Nov;129(11):1242-9 [19863319.001]
  • [Cites] Head Neck Pathol. 2008 Jun;2(2):49-59 [20614323.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):590-6 [15363811.001]
  • [Cites] J Cell Biol. 1975 Aug;66(2):305-15 [1095598.001]
  • [Cites] J Biol Chem. 1985 Apr 25;260(8):5087-97 [3886649.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]
  • [Cites] Eur J Surg Oncol. 2005 Oct;31(8):905-11 [16005600.001]
  • [Cites] J Surg Oncol. 2006 Jan 1;93(1):80-5 [16353190.001]
  • [Cites] G Ital Med Lav Ergon. 2005 Oct-Dec;27(4):422-6 [16512339.001]
  • [Cites] J Cell Biol. 2006 Sep 11;174(6):863-75 [16966425.001]
  • [Cites] BMC Cancer. 2006;6:241 [17029629.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jan;26(1):71-5 [17197900.001]
  • [Cites] J Craniomaxillofac Surg. 2007 Jan;35(1):21-9 [17267229.001]
  • [Cites] World J Urol. 2007 Mar;25(1):73-80 [17021824.001]
  • [Cites] Chin Med J (Engl). 2007 Mar 5;120(5):375-9 [17376306.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2007 Apr;15(2):95-8 [17413409.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):530-7 [17425380.001]
  • [Cites] Dis Markers. 2007;23(3):153-60 [17473384.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6844-53 [17638895.001]
  • [Cites] Am J Rhinol. 2007 Nov-Dec;21(6):664-9 [18201444.001]
  • [Cites] J Histochem Cytochem. 2008 Feb;56(2):193-9 [17998567.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Sep;134(9):947-51 [18343949.001]
  • (PMID = 20596974.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC2811625
  •  go-up   go-down


13. Albores-Saavedra J, Galliani C, Chable-Montero F, Batich K, Henson DE: Mucin-containing Rokitansky-Aschoff sinuses with extracellular mucin deposits simulating mucinous carcinoma of the gallbladder. Am J Surg Pathol; 2009 Nov;33(11):1633-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rokitansky-Aschoff sinuses (R-As) are epithelial invaginations that extend down the gallbladder wall through the smooth muscle gaps and by this pathway they reach the subserosal connective tissue.
  • Three cases of mucin-containing R-As accompanied by abundant extracellular mucin deposits with epithelial strips, glands and papillary structures were misinterpreted as mucinous carcinomas.
  • Detached fragments of biliary epithelium, small glands, and papillary structures lacking cytologic atypia and mitotic figures were identified in the abundant mucin deposits located in the subserosa of 3 cases.
  • The overlying surface gallbladder epithelium exhibited papillary hyperplasia with focal intestinal metaplasia in 2 patients, one of which had metachromatic leukodystrophy.
  • The lack of reactivity for carcinoembryonic antigen and p53 and the low proliferative activity as measured by MIB-1 labeling index provided additional support to the benign nature of the lesion.
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Cell Proliferation. Child, Preschool. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucous Membrane / metabolism. Mucous Membrane / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 Jan;35(1):153-4 [21164300.001]
  • (PMID = 19738458.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


14. Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM: Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res; 2005 May 1;65(9):3726-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial ovarian cancer derived from the human ovarian surface epithelium (HOSE) is the leading cause of death from gynecologic malignancies among American women.
  • Immunocytochemistry studies in 30 clinical specimens revealed overexpression of CYP1A1 in various types of ovarian cancers compared with benign epithelia and frequent localization of the enzyme to cancer cell nuclei.
  • [MeSH-minor] Alternative Splicing. Base Sequence. Benzo(a)pyrene / pharmacokinetics. Carcinogens / pharmacokinetics. Cell Line, Tumor. Cell Nucleus / enzymology. Cell Transformation, Neoplastic / drug effects. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Epithelium / enzymology. Epithelium / pathology. Estradiol / pharmacokinetics. Female. Humans. Isoenzymes. Mitochondria / enzymology. Molecular Sequence Data. Ovary / cytology. Ovary / drug effects. Ovary / enzymology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Subcellular Fractions / enzymology. Transfection

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867368.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA94221
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Isoenzymes; 0 / RNA, Messenger; 3417WMA06D / Benzo(a)pyrene; 4TI98Z838E / Estradiol; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  •  go-up   go-down


15. Noske A, Denkert C, Schober H, Sers C, Zhumabayeva B, Weichert W, Dietel M, Wiechen K: Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer; 2005 Feb;41(3):461-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we analysed the expression of gelsolin in 241 matched cDNA pairs from human normal and tumour tissues using a Cancer Profiling Array.
  • On a protein level, we examined the expression of gelsolin in human ovarian cancer cell lines and in a set of 110 cases of human benign and malignant ovarian tumours.
  • Low levels of gelsolin protein were observed in four of six ovarian carcinoma cell lines, in contrast to its expression in normal ovarian surface epithelial cells.
  • In addition, we found a reduced expression of gelsolin in borderline tumours and ovarian carcinomas compared with the epithelium of normal ovaries and benign adenomas.
  • Re-expression of gelsolin in OAW42 and ES-2 cells resulted in a suppression of tumour cell survival in vitro.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Down-Regulation. Female. Humans. Immunohistochemistry. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691647.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gelsolin
  •  go-up   go-down


16. Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M, Kikkawa F: Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol; 2005 Jul;98(1):11-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
  • P-LAP is a cell surface aminopeptidase, and is a synonym for oxytocinase.
  • The authors evaluated P-LAP and GLUT4 expression in benign, borderline, and malignant ovarian epithelia.
  • METHODS: Histologic sections of formalin-fixed, paraffin-embedded specimens from 11 patients with benign serous or mucinous cystadenomas, 14 patients with serous or mucinous borderline tumors, and 80 patients with epithelial-ovarian adenocarcinomas (29 serous, 17 endometrioid, 14 mucinous, and 20 clear cell adenocarcinomas) were stained for P-LAP and GLUT4 using each polyclonal antibody.
  • RESULTS: P-LAP immunoreactivity was detected in 2 of 11 benign cystadenomas.
  • None of the 11 benign ovarian tumors showed any immunoreactivity for GLUT4.
  • CONCLUSIONS: P-LAP and GLUT4 are available not only for the evaluation of ovarian epithelial malignancy, but also as targets for molecular therapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Growth Processes / physiology. Cell Line, Tumor. Epithelium / enzymology. Epithelium / metabolism. Female. Glucose Transporter Type 4. Humans. Middle Aged. Neoplasm Invasiveness. Ovarian Diseases / enzymology. Ovarian Diseases / metabolism. Ovarian Diseases / pathology. Transfection

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907336.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 4; 0 / Monosaccharide Transport Proteins; 0 / Muscle Proteins; 0 / SLC2A4 protein, human; EC 3.4.11.3 / Cystinyl Aminopeptidase; EC 3.4.11.3 / leucyl-cystinyl aminopeptidase
  •  go-up   go-down


17. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF, Schorge JO: Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res; 2005 Aug 1;11(15):5365-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation profile of ovarian epithelial neoplasms.
  • PURPOSE: Ovarian carcinomas are believed to arise de novo from surface epithelium, but the actual molecular pathogenesis is unknown.
  • The aim of this study was to compare the promoter hypermethylation profiles of ovarian epithelial neoplasms to better understand the role of epigenetic silencing in carcinogenesis.
  • EXPERIMENTAL DESIGN: We analyzed the DNA promoter methylation status of eight tumor suppressor and cancer-related genes (p16, RARbeta, E-cadherin,H-cadherin, APC, GSTP1, MGMT, RASSF1A) in 23 benign cystadenomas, 23 low malignant potential (LMP) tumors, and 23 invasive carcinomas by methylation-specific PCR.
  • RESULTS: Benign cystadenomas exhibited promoter hypermethylation in only two genes, p16 (13%) and E-cadherin (13%).
  • CONCLUSIONS: Promoter hypermethylation is a frequent epigenetic event that occurs most commonly in invasive epithelial ovarian carcinomas.
  • The profile of aberrant methylation suggests that an accumulation of events at specific genes may trigger malignant transformation of some benign cystadenomas and LMP tumors.
  • [MeSH-major] DNA Methylation. Neoplasms, Glandular and Epithelial / genetics. Ovarian Neoplasms / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / genetics. Adult. Aged. Aged, 80 and over. Cadherins / genetics. Carcinoma / genetics. Carcinoma / pathology. Cell Transformation, Neoplastic. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cystadenoma / genetics. DNA / metabolism. Epigenesis, Genetic. Female. Gene Silencing. Glutathione S-Transferase pi / genetics. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. O(6)-Methylguanine-DNA Methyltransferase / genetics. Polymerase Chain Reaction. Receptors, Retinoic Acid / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061849.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / H-cadherin; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta; 9007-49-2 / DNA; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


18. Miot HA, Miot LD, da Costa AL, Matsuo CY, Stolf HO, Marques ME: Association between solitary keratoacanthoma and cigarette smoking: a case-control study. Dermatol Online J; 2006;12(2):2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solitary keratoacanthoma (KA) is a common benign epithelial tumor of the skin characterized by rapid growth and a tendency toward spontaneous regression.

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638395.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC: Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol; 2008 May;109(2):234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Western blot compared CEACAM6 expression in normal human ovarian surface epithelium (HOSE) and ovarian cancer cell lines.
  • 100-fold CEACAM6 overexpression (qRT-PCR) was demonstrated in 13/16 (81%) borderline, low-grade, and high-grade invasive MON's, compared to 5/50 (10%) serous and 1/5 (20%) benign mucinous samples.
  • CEACAM6 expression was not different between borderline and invasive MON's (p=0.55) or across tumor stage (p=0.76).
  • None of the serous or benign mucinous tumors exhibited CEACAM6 staining.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Blotting, Western. Cell Line, Tumor. Cystadenocarcinoma, Serous / metabolism. Epithelium / metabolism. Female. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Ovary / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Staining and Labeling. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331757.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CEACAM6 protein, human; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins
  •  go-up   go-down


20. Kinkor Z, Michal M: [Syndrome of pseudomyxoma peritonei--description of three cases and survey of the problem]. Ceska Gynekol; 2005 Jan;70(1):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Pseudomyxoma peritonei is a clinical syndrome defined as presence of massive mucinous, viscous material in the peritoneal cavity, both floating and adhering to serosal surface (jelly-belly).
  • The histologic examination should always follow with detailed and precise description of the epithelial component.
  • The cytological and structural quality of the epithelium constitutes two basic forms with entirely different nature biology and prognosis.
  • First and more frequent, so-called disseminated peritoneal adenomucinosis, where primary low grade (benign) mucinous appendiceal tumor is almost constant finding, often recurs but displays favorable prognosis.

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779299.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


21. Natarajan E, Woo SB: Benign alveolar ridge keratosis (oral lichen simplex chronicus): A distinct clinicopathologic entity. J Am Acad Dermatol; 2008 Jan;58(1):151-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign alveolar ridge keratosis (oral lichen simplex chronicus): A distinct clinicopathologic entity.
  • Benign alveolar ridge keratosis is a common benign white papule or plaque that occurs on the keratinized gingiva of the maxillary or mandibular alveolar ridge that is probably traumatic/frictional in origin, with characteristic histologic features, similar to those of lichen simplex chronicus of the skin.
  • This is a retrospective study of 108 consecutive specimens displaying characteristic histopathologic features of benign alveolar ridge keratosis accessioned during a 36-month period.
  • The epithelium exhibited slight surface papillomatosis and acanthosis in the form of long, tapered rete ridges that frequently anastomosed at the base.
  • These features are similar if not identical to lichen simplex chronicus of the skin, a benign condition caused by chronic irritation.
  • Ten randomly selected cases were immunostained for p16INK4A(p16), a tumor suppressor protein expressed in dysplastic epithelium.
  • Benign alveolar ridge keratosis is a specific clinicopathologic entity that should be removed from the category of leukoplakia as is currently the practice for clinical white lesions with a specific, consistently recognizable histologic appearance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158926.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


22. Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD: Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol; 2007 Jun;105(3):578-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of mammaglobin B in epithelial ovarian carcinomas.
  • In order to evaluate its potential as a novel ovarian cancer biomarker, in this study we quantified and compared Mammaglobin B expression in various histologic types of epithelial ovarian carcinomas (EOC).
  • METHODS: Mammaglobin B expression was evaluated by real-time PCR and/or immunohistochemistry in fresh-frozen biopsies and paraffin-embedded tissues derived from a total of 137 patients including 69 primary EOC with different histologies, 28 serous papillary omental metastasis, 8 borderline tumors, 26 benign cystadenomas and 14 normal ovaries.
  • In contrast, normal human ovarian surface epithelium (HOSE) expressed negligible levels of Mammaglobin B mRNA (EOC versus HOSE, p<0.01).
  • In agreement with real-time PCR results, EOC were found to express significantly higher levels of Mammaglobin B protein when compared to normal ovaries and benign cystadenomas (p<0.01).
  • [MeSH-major] Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / immunology. Uteroglobin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Cell Line, Tumor. Female. Gene Expression. Humans. Immunohistochemistry. Mammaglobin B. Middle Aged. Myelin Proteins. Polymerase Chain Reaction. Proteolipids. Secretoglobins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343903.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin B; 0 / Myelin Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / SCGB2A1 protein, human; 0 / Secretoglobins; 9060-09-7 / Uteroglobin
  •  go-up   go-down


23. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG: An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol; 2005 Aug;29(8):1034-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian serous carcinoma (OSC) is the most common ovarian epithelial malignancy.
  • In this scheme, low-grade OSC arises in a stepwise fashion from a benign serous cystadenoma through a usual serous borderline tumor through a micropapillary variant of serous borderline tumor.
  • In contrast, the more common high-grade OSC arises de novo from the ovarian surface epithelium or the epithelium of cortical inclusion cysts with an as yet unrecognized precursor lesion.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cystadenoma, Serous / chemistry. Cystadenoma, Serous / pathology. Ki-67 Antigen / analysis. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / pathology. Peptide Fragments / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-kit / analysis. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Female. Humans. Inhibitor of Apoptosis Proteins. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Osteopontin. Sialoglycoproteins / analysis. WT1 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006797.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / HER2-neu-derived peptide (654-662); 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins; 106441-73-0 / Osteopontin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


24. Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, Karavasilis V, Pavlidis N, Agnantis NJ: Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors. Histol Histopathol; 2006 04;21(4):341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
  • This study examined the immunohistochemical expression of MTs in benign, borderline and malignant tumors of ovarian surface epithelium and the possible correlations with clinicopathological parameters and survival.
  • A total of 87 cases with diagnosis of ovarian surface epithelial tumors were included.
  • Specifically, 21 cases of benign cystadenomas (11 serous and 10 mucinous), 14 borderline (low malignant potential tumors, 8 mucinous and 6 serous) and 52 cases of ovarian cancer were analysed.
  • Immunohistochemical expression of MT (cut-off level > 10% of tumor cells) was clearly associated with malignancy.
  • A statistically significant correlation was found between the expression of MT in cancer cases and benign tumors (p < 0.0001) and cancer cases and borderline tumors p = 0.003.
  • MT constitutes a marker that characterizes aggressiveness and a high malignant potential in ovarian epithelial tumors.
  • In diagnostic problems MT may help distinguish between benign, borderline and malignant tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Differentiation / genetics. Cell Proliferation. Cystadenoma, Mucinous / chemistry. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / chemistry. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / pathology. Diagnosis, Differential. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / physiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437378.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; 9038-94-2 / Metallothionein
  •  go-up   go-down


25. Brooks SA, Carter TM, Bennett EP, Clausen H, Mandel U: Immunolocalisation of members of the polypeptide N-acetylgalactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast cancer. Acta Histochem; 2007;109(4):273-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolocalisation of members of the polypeptide N-acetylgalactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast cancer.
  • The cells were chosen to represent a range of phenotypes from 'normal'/benign (HMT 3,522), primary, non-metastatic breast cancer (BT 474), to aggressive, metastatic breast cancer (ZR75-1, T47D, MCF-7, DU 4,475).
  • GalNAc-T1 and -T2 were detectable at low levels in all cell lines studied. ppGalNAc-T4, which has never been described in breast, was very weakly detectable in BT 474, MCF7 and T47D. ppGalNAc-T3 and -T6 were weakly detectable or undetectable, respectively, in the cell line HMT 3,522 derived from 'normal'/benign breast epithelium, but were readily detectable in all malignant cell lines.
  • Thus, a broader range of ppGalNAc-T's were detectable in the malignant cell lines in comparison to the 'normal'/benign cells, where only the 'housekeeping' ppGalNAc-T1 and -T2 were present.
  • [MeSH-minor] Animals. Antibodies, Monoclonal. Biology. Cell Line, Tumor. Glycosylation. Humans. Immunohistochemistry. Mice

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448526.001).
  • [ISSN] 0065-1281
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 2.4.1.- / N-Acetylgalactosaminyltransferases; EC 2.4.1.41 / polypeptide N-acetylgalactosaminyltransferase
  •  go-up   go-down


26. Xiang H, Ding W, Liu F, Ren GP, Wang ZM, Zhu XZ: [Clinicopathologic analysis of mixed epithelial and stromal tumor of kidney and adult cystic nephroma]. Zhonghua Bing Li Xue Za Zhi; 2009 Jul;38(7):436-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of mixed epithelial and stromal tumor of kidney and adult cystic nephroma].
  • OBJECTIVE: To study the clinicopathologic features, immunophenotype and differential diagnosis of mixed epithelial and stromal tumor of kidney (MEST) and adult cystic nephroma (CN).
  • One was composed of a mixture of solid and cystic elements, while the remaining case showed a multicystic cut surface bridged by thick fibrous septa.
  • The glandular structures in 2 of the cases were partially lined by endometrial or tubal epithelium.
  • In contrast, the thin-walled cystic spaces in CN were lined by a single layer of epithelium.Immunohistochemical study showed that the epithelial cells were positive for pan-cytokeratin and epithelial membrane antigen.
  • CONCLUSIONS: Both MEST and CN are uncommon renal neoplasm.
  • Most of them run a benign clinical course.
  • [MeSH-major] Epithelial Cells / pathology. Kidney Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781188.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Desmin; 0 / Receptors, Estrogen; 0 / Vimentin
  •  go-up   go-down


27. Salani R, Neuberger I, Kurman RJ, Bristow RE, Chang HW, Wang TL, Shih IeM: Expression of extracellular matrix proteins in ovarian serous tumors. Int J Gynecol Pathol; 2007 Apr;26(2):141-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of this study were to perform a comprehensive expression analysis of the genes encoding extracellular matrix proteins and to investigate the expression pattern in one of these proteins, syndecan 1, in normal ovarian epithelium as well as benign and malignant ovarian serous tumors.
  • As compared with normal ovarian surface epithelium, we found overexpression of syndecan 1, collagen type IV alpha 2, elastin microfibril interfase located protein 1, and laminin 5 in ovarian serous carcinomas.
  • Using a syndecan 1-specific monoclonal antibody, we demonstrated that syndecan 1 was expressed in 30.4% of high-grade serous carcinomas, 29.7% of low-grade carcinomas and serous borderline tumors, but none of benign serous cystadenomas and ovarian surface epithelium.
  • In summary, ovarian carcinomas exhibit up-regulated expression of several extracellular matrix proteins, and syndecan 1 represents a novel tumor-associated marker in ovarian serous carcinomas.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Collagen Type IV / genetics. Collagen Type IV / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Laminin / genetics. Laminin / metabolism. Membrane Glycoproteins / genetics. Membrane Glycoproteins / metabolism. Syndecan-1 / genetics. Syndecan-1 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413980.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV; 0 / Extracellular Matrix Proteins; 0 / Laminin; 0 / Membrane Glycoproteins; 0 / Syndecan-1; 0 / elastin microfibril interface located protein
  •  go-up   go-down


28. Kline RC, Bazzett-Matabele LB: Adnexal masses and malignancies of importance to the colorectal surgeon. Clin Colon Rectal Surg; 2010 Jun;23(2):63-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article, the authors review both benign and malignant ovarian masses, as the colorectal surgeon who encounters an adnexal mass at the time of surgery should be aware of the steps necessary for surgical staging and optimal tumor resection.Ovarian tumors-most of which are benign-are divided into three major categories, in order of frequency: epithelial, germ cell, and sex cord-stromal tumors.
  • Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis.Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant.
  • The more common sex cord-stromal tumors include granulosa stromal cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas.Surgical staging and optimal tumor resection are also addressed, with a focus on epithelial malignancies, as they are the most relevant to colorectal surgeons.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):77-81 [11277654.001]
  • [Cites] JAMA. 1983 Dec 9;250(22):3072-6 [6358558.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):30-5 [16021055.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):383-90 [17005244.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):775-82 [19305319.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(4):343-51 [2246093.001]
  • [Cites] Curr Top Pathol. 1989;78:85-109 [2651026.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:15-25 [3665859.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):139-44 [2680797.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):921-6 [2685680.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):983-9 [3373267.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • (PMID = 21629623.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2967325
  • [Keywords] NOTNLM ; Adnexal masses / ovarian cancer / ovarian cysts
  •  go-up   go-down


29. Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S, Surmacz E: Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res; 2006 Mar 1;12(5):1447-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate whether the leptin system could become a target in breast cancer therapy, we examined the expression of leptin and its receptor (ObR) in primary and metastatic breast cancer and noncancer mammary epithelium.
  • EXPERIMENTAL DESIGN: The expression of leptin and ObR was examined by immunohistochemistry in 148 primary breast cancers and 66 breast cancer metastases as well as in 90 benign mammary lesions.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Leptin / metabolism. Obesity / complications. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / metabolism. Breast / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Case-Control Studies. Cell Hypoxia. Disease Progression. Estradiol / pharmacology. Female. Humans. Insulin / pharmacology. Insulin-Like Growth Factor I / pharmacology. Middle Aged. Neoplasms / genetics. Neoplasms / metabolism. Neoplasms / pathology. Receptors, Leptin. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Obesity.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533767.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin; 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / leptin receptor, human; 4TI98Z838E / Estradiol; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


30. Acevedo-Henao CM, Talagas M, Marianowski R, Pradier O: Recurrent inverted papilloma with intracranial and temporal fossa involvement: A case report and review of the literature. Cancer Radiother; 2010 Jun;14(3):202-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inverted papilloma (IP) is a rare nasosinusal benign tumour, with epithelium surface inversion to inside the stroma.
  • As a conclusion, inverted papilloma is a benign tumour with an aggressive course, tendency to recurrence and progression to malignancy.
  • [MeSH-minor] Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Disease Progression. Ear, Middle / pathology. Facial Paralysis / etiology. Fatal Outcome. Hearing Loss, Conductive / etiology. Humans. Male. Middle Aged. Nasal Obstruction / etiology. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / surgery. Petrous Bone / pathology. Petrous Bone / surgery. Radiotherapy, Conformal. Reoperation. Temporal Lobe / pathology. Temporal Lobe / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20418144.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 21
  •  go-up   go-down


31. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R: Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer; 2005 Jan 20;113(3):372-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
  • Although proteases in general have been implicated in the remodeling of the extracellular tumor microenvironment, the role of cell surface receptors activated by proteolysis is now emerging.
  • In contrast, no hPar1 expression was detected on the cell surface of normal ovarian epithelium.
  • In early stages of ovarian carcinoma (Ia), the contra lateral normal ovary showed strong PAR1 expression as opposed to the lack of expression in the ovarian epithelium obtained from normal individuals.
  • Phosphorylated FAK was seen in invasive ovarian carcinoma, but not in the normal ovarian epithelium.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Epithelium / metabolism. Epithelium / pathology. Female. Focal Adhesion Kinase 1. Focal Adhesion Protein-Tyrosine Kinases. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. In Situ Hybridization. Integrins / genetics. Integrins / metabolism. Neoplasm Invasiveness / pathology. Ovary / metabolism. Ovary / pathology. Phosphorylation. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Vitronectin / genetics. Receptors, Vitronectin / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15455382.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrins; 0 / RNA, Messenger; 0 / Receptor, PAR-1; 0 / Receptors, Vitronectin; 0 / integrin alphaVbeta5; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / PTK2 protein, human
  •  go-up   go-down


32. Thomas S, Chigurupati S, Anbalagan M, Shah G: Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor. Mol Endocrinol; 2006 Aug;20(8):1894-911
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of human (h) calcitonin (CT) and its receptor (CTR) is localized to basal epithelium in benign prostates but is distributed in whole epithelium of malignant prostates.
  • Moreover, the abundance of hCT and CTR mRNA in primary prostate tumors positively correlates with the tumor grade.
  • These results, when combined with our other results, that the expression of hCT in primary PCs increase with tumor grade, suggest an important role for hCT in the progression of PC to a metastatic phenotype.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16574742.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096534; United States / NCI NIH HHS / CA / CA96534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / Plaur protein, mouse; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; 9007-12-9 / Calcitonin; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


33. Abd El-Wahed MM: Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. J Egypt Natl Canc Inst; 2005 Sep;17(3):173-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features.
  • BACKGROUND AND PURPOSE: Maspin is an inhibitor of serine proteinases with tumor suppressor activity that is down-regulated in breast and prostate cancer, but overexpressed in pancreatic carcinoma.
  • The aim of the present study was to evaluate maspin expression in ovarian epithelial neoplasms and correlate its expression with some clinicopathologic parameters.
  • MATERIAL AND METHODS: Seventy eight paraffin embedded ovarian specimens from patients with ovarian epithelial neoplasms comprised the material of this study.
  • They included 18 benign, 14 low malignant potential (LMP) and 46 malignant epithelial ovarian neoplasms, in addition to seven specimens from normal ovarian tissues as a control.
  • RESULTS: Immunohistochemical study of maspin expression using streptavidin biotin immunoperoxidase method revealed that, normal ovarian surface epithelium did not express maspin as well as benign serous and mucinous ovarian epithelial neoplasm.
  • However, all benign Brenner ovarian tumors were maspin positive.
  • On the other hand, 57.14% of LMP tumors showed weak maspin expression and 63% of malignant ovarian epithelial tumors showed maspin expression with 39.1% over expression.
  • Moreover, variation in maspin expression between Brenner tumor and other epithelial surface ovarian tumors may indicate that the different histological types probably represent distinct disease entities and involve different molecular pathways.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Serine Proteinase Inhibitors / metabolism
  • [MeSH-minor] Adolescent. Adult. Brenner Tumor / metabolism. Brenner Tumor / pathology. CA-125 Antigen / analysis. Carcinoembryonic Antigen / analysis. Epithelium / metabolism. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Ovary / metabolism. Serpins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799655.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins
  •  go-up   go-down


34. Crivelini MM, Soubhia AM, Felipini RC: Study on the origin and nature of the adenomatoid odontogenic tumor by immunohistochemistry. J Appl Oral Sci; 2005 Dec;13(4):406-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study on the origin and nature of the adenomatoid odontogenic tumor by immunohistochemistry.
  • The adenomatoid odontogenic tumor (AOT) is a clinically benign lesion.
  • Discussions about the AOT hamartomatous or neoplastic nature, and the probable odontogenic epithelial cell it originates from still exist.
  • This research aimed to study and discuss the subject by the immunohistochemical detection of cytokeratins, laminin, collagen IV, PCNA and p53 in 8 tumor samples and 8 dental follicle samples containing reduced enamel epithelium.
  • Laminin, found on the luminal surface of adenomatoid structures, was compatible with the reduced enamel epithelium during the "protective stage of amelogenesis".
  • PCNA specifically labelled the spindled areas and peripheral cords of the AOT, indicating that these areas are responsible for tumor growth.
  • After considerations about pathogenesis, the authors suggested that the nature of AOT is hamartomatous with histogenesis from the reduced enamel epithelium.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20865228.001).
  • [ISSN] 1678-7757
  • [Journal-full-title] Journal of applied oral science : revista FOB
  • [ISO-abbreviation] J Appl Oral Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


35. Mortuaire G, Pasquesoone X, Leroy X, Chevalier D: Respiratory epithelial adenomatoid hamartomas of the sinonasal tract. Eur Arch Otorhinolaryngol; 2007 Apr;264(4):451-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Respiratory epithelial adenomatoid hamartomas of the sinonasal tract.
  • We report the clinicopathologic features of two cases of respiratory epithelial adenomatoid harmartoma (REAH) of the sinonasal tract.
  • Histologically, these lesions were characterized by a glandular proliferation lined by ciliated respiratory epithelium originated from the surface epithelium.
  • Fine histopathological analysis is necessary to avoid aggressive surgery for this benign lesion.
  • [MeSH-major] Adenomatoid Tumor / pathology. Hamartoma / pathology. Paranasal Sinus Neoplasms / pathology. Respiratory Mucosa / pathology
  • [MeSH-minor] Adult. Endoscopy. Female. Humans. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 May;97(5):607-12 [15153874.001]
  • [Cites] Am J Otolaryngol. 2004 Jul-Aug;25(4):282-4 [15239039.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Aug;104(8):639-45 [7639474.001]
  • [Cites] J Laryngol Otol. 2004 Jul;118(7):558-60 [15318966.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2003 Jun;67(6):669-72 [12745162.001]
  • [Cites] Acta Otolaryngol. 2002 Jun;122(4):398-400 [12125996.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 2004;125(1):45-8 [15244029.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2005 Jan;69(1):87-91 [15627453.001]
  • (PMID = 17089137.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Chen LL, Ye F, Lü WG, Yu Y, Chen HZ, Xie X: Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J Obstet Gynaecol Res; 2009 Apr;35(2):212-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma.
  • OBJECTIVE: The aim of this study was to detect expression of different cytokines in epithelial ovarian carcinoma (EOC) cells and normal ovarian surface epithelial (OSE) cells in vitro and the levels of those with elevated expression in the EOC patients, and to analyze the contribution of cytokine profiles to tumor immune deficiency.
  • The levels of leukemia inhibitory factor (LIF), interleukin-10 (IL-10), IL-4, and transforming growth factor-beta1 (TGF-beta1) in peritoneal fluids and sera in the patients with EOC and benign gynecological tumors were detected by enzyme-linked immunosorbent assay.
  • Both LIF and IL-10 levels were more increased in ascites of EOC patients than in those in benign gynecological tumor patients (P < 0.05).
  • No difference of TGF-beta1 value was detected between patients with EOC and benign gynecological tumors.
  • CONCLUSION: Epithelium ovarian carcinoma cells can produce more LIF, IL-10 and IL-4 than OSE cells, and contribute to the elevated levels of those cytokines in EOC patients, which probably participates in the development of immune deficiency in the peritoneal cavity of EOC patients.
  • [MeSH-major] Cytokines / analysis. Neoplasms, Glandular and Epithelial / immunology. Ovarian Neoplasms / immunology
  • [MeSH-minor] Adult. Cell Line, Tumor. Female. Humans. Interleukin-10 / analysis. Interleukin-4 / analysis. Leukemia Inhibitory Factor / analysis. Transforming Growth Factor beta1 / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335794.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cytokines; 0 / Leukemia Inhibitory Factor; 0 / Transforming Growth Factor beta1; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4
  •  go-up   go-down


37. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res; 2005 Nov 15;65(22):10602-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Papillary serous low malignant potential (LMP) tumors are characterized by malignant features and metastatic potential yet display a benign clinical course.
  • The role of LMP tumors in the development of invasive epithelial cancer of the ovary is not clearly defined.
  • Affymetrix U133 Plus 2.0 microarrays (Santa Clara, CA) were used to interrogate 80 microdissected serous LMP tumors and invasive ovarian malignancies along with 10 ovarian surface epithelium (OSE) brushings.
  • Gene expression profiles for each tumor class were used to complete unsupervised hierarchical clustering analyses and identify differentially expressed genes contributing to these associations.
  • Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype.
  • [MeSH-minor] Cluster Analysis. Female. Gene Expression Profiling. Humans. Neoplasm Staging. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288054.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


38. Penumatsa K, Edassery SL, Barua A, Bradaric MJ, Luborsky JL: Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res; 2010;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we compared ALDH1 expression in normal ovary and benign and malignant ovarian tumors to determine if ALDH1 expression is altered in ovarian cancer.
  • RESULTS: ALDH1 mRNA expression was significantly reduced (p < 0.01; n = 5) in malignant tumors compared to normal ovaries and benign tumors.
  • The proportion of ALDH1+ cells was significantly lower in malignant tumors (17.1 ± 7.61%; n = 5) compared to normal ovaries (37.4 ± 5.4%; p < 0.01; n = 5) and benign tumors (31.03 ± 6.68%; p < 0.05; n = 5).
  • ALDH1+ cells occurred in the stroma and surface epithelium in normal ovary and benign tumors, although surface epithelial expression varied more in benign tumors.
  • Localization of ALDH1 was heterogeneous in malignant tumor cells and little ALDH1 expression occurred in poorly differentiated malignant tumors.
  • In benign tumors the distribution of ALDH1 had features of both normal ovary and malignant tumors.
  • CONCLUSIONS: Total ALDH1 expression is significantly reduced in malignant ovarian tumors while it is relatively unchanged in benign tumors compared to normal ovary.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Immunol. 2009 Feb;21(1):22-7 [18778953.001]
  • [Cites] Mol Cancer. 2008;7:87 [19025616.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1144-53 [19293794.001]
  • [Cites] Fertil Steril. 2010 Dec;94(7):2636-41 [20522323.001]
  • [Cites] Int J Cancer. 1994 Mar 1;56(5):743-8 [8314353.001]
  • [Cites] J Cell Physiol. 2000 Oct;185(1):1-20 [10942515.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3638-45 [11014218.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6744-9 [11118061.001]
  • [Cites] Annu Rev Nutr. 2002;22:347-81 [12055350.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Chem Biol Interact. 2003 Feb 1;143-144:201-10 [12604205.001]
  • [Cites] J Biochem Mol Toxicol. 2003;17(1):7-23 [12616643.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1013-20 [12631600.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1648-55 [15178579.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] FASEB J. 1991 Nov;5(14):2924-33 [1661245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1092-100 [16969345.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):3724-33 [17785809.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10538-45 [17974998.001]
  • [Cites] J Cell Sci. 1991 Nov;100 ( Pt 3):657-66 [1808213.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1146-53 [18644979.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):2236-52 [18681906.001]
  • [Cites] Int Immunol. 2009 Apr;21(4):361-77 [19190084.001]
  • [Cites] Mol Cancer Res. 2009 Mar;7(3):330-8 [19276181.001]
  • [Cites] Birth Defects Res C Embryo Today. 2009 Mar;87(1):64-89 [19306350.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):817-23 [19329942.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Nucl Recept Signal. 2009;7:e002 [19381305.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] Breast Cancer Res Treat. 2010 Aug;123(1):109-11 [19946740.001]
  • [Cites] Lab Invest. 2010 Feb;90(2):234-44 [20010854.001]
  • [Cites] Clin Cancer Res. 2010 Feb 1;16(3):876-87 [20103682.001]
  • [Cites] PLoS One. 2010;5(4):e10277 [20422001.001]
  • [Cites] Cell Commun Signal. 2010;8(1):6 [20459772.001]
  • [Cites] J Microsc. 1987 Sep;147(Pt 3):229-63 [3430576.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):146-7 [7707390.001]
  • [Cites] Neurobiol Aging. 1993 Jul-Aug;14(4):275-85 [8367009.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S52-62 [8811064.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):54-62 [9103391.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2033-8 [9815594.001]
  • [Cites] J Investig Med. 1996 Feb;44(2):42-6 [8689400.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2157-63 [12727970.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Mol Cancer. 2004 Oct 7;3:27 [15471544.001]
  • [Cites] J Endocrinol. 2004 Oct;183(1):19-28 [15525570.001]
  • [Cites] Hum Genomics. 2005 Jun;2(2):138-43 [16004729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11707-12 [16857736.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Jul;72(4):281-9 [17111384.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):340-9 [17920722.001]
  • [Cites] Toxicol Sci. 2008 Jan;101(1):51-64 [17998271.001]
  • [Cites] Endocrinology. 2008 Sep;149(9):4307-11 [18556344.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):697-720 [18611112.001]
  • (PMID = 21176222.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022900
  •  go-up   go-down


39. Ødegaard E, Staff AC, Kaern J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B: The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol; 2006 Mar;100(3):462-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: AP-2gamma was detected in the nucleus of tumor cells in 28/75 (37%) borderline tumors, 13/22 (59%) FIGO stage I carcinomas, and 255/306 (83%) advanced-stage carcinomas (P < 0.001, Chi-square test).
  • Benign ovaries were uniformly negative.
  • CONCLUSIONS: AP-2gamma expression is upregulated in advanced-stage ovarian carcinoma compared to early-stage carcinomas, borderline tumors, and the ovarian surface epithelium, and AP-2gamma is specifically localized to cancer cells in effusions, suggesting a role in tumor progression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Nucleus / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Proto-Oncogene Proteins c-kit / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216317.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factor AP-2; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


40. Jundt G, Reichart PA: [Benign odontogenic ectomesenchymal tumors]. Pathologe; 2008 May;29(3):199-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign odontogenic ectomesenchymal tumors].
  • The group of odontogenic ectomesenchymal tumors consists of odontogenic fibroma (epithelium-rich and epithelium-poor types), odontogenic myxoma, and cementoblastoma.
  • Whereas odontogenic fibromas and cementoblastomas are very rare lesions, odontogenic myxoma is the fourth common odontogenic tumor, preceded only by keratocystic odontogenic tumor, the odontomas, and ameloblastoma.
  • The differentiation of odontogenic fibroma and myxoma from other lesions, especially from normal structures such as dental follicles and papillae, may be challenging if the X-ray appearance (localized osteolysis containing a tooth) is not appreciated and subtle histological clues (remainders of inner enamel epithelium at the surface of the lesion, dentin fragments) are not properly recognized.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dentomaxillofac Radiol. 2007 Oct;36(7):423-7 [17881604.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1980 Nov;50(5):425-32 [6935598.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Jan;36(1):20-5 [17156974.001]
  • [Cites] Cell Mol Life Sci. 2004 Oct;61(19-20):2510-22 [15526158.001]
  • [Cites] J Laryngol Otol. 2000 Jul;114(7):533-5 [10992937.001]
  • [Cites] J Oral Maxillofac Surg. 1993 Jul;51(7):762-7; discussion 767-8 [8509916.001]
  • [Cites] J Oral Pathol Med. 1996 Nov;25(10):556-61 [8986968.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):240-5 [16505272.001]
  • [Cites] J Dent Res. 2005 May;84(5):390-406 [15840773.001]
  • [Cites] Oral Oncol. 2006 Sep;42(8):757-8 [16679047.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Mar;93(3):311-20 [11925541.001]
  • [Cites] J Oral Maxillofac Surg. 1995 May;53(5):518-21 [7722719.001]
  • [Cites] Scand J Dent Res. 1984 Aug;92(4):352-7 [6591371.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1996 Jun;105(6):490-4 [8638904.001]
  • [Cites] Periodontol 2000. 2006;41:196-217 [16686935.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] J Oral Maxillofac Surg. 1985 Dec;43(12 ):987-90 [3864957.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Sep;98 (3):295-300 [15356466.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1982 Jul;54(1):40-8 [6750498.001]
  • (PMID = 18392828.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Lindholm PF, Lu Y, Adley BP, Vladislav T, Jovanovic B, Sivapurapu N, Yang XJ, Kajdacsy-Balla A: Role of monocyte-lineage cells in prostate cancer cell invasion and tissue factor expression. Prostate; 2010 Nov 1;70(15):1672-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tissue factor (TF) is a cell surface glycoprotein intricately related to blood coagulation and inflammation.
  • Immunohistochemistry was performed to identify prostate tissue CD68 positive monocyte-derived cells and prostate epithelial TF expression.
  • Prostate cancer tissues contained more CD68 positive cells in the stroma and epithelium (145 ± 53/mm(2)) than benign prostate (108 ± 31/mm(2)).
  • Prostatic adenocarcinoma demonstrated significantly increased TF expression compared with benign prostatic epithelium.
  • [MeSH-minor] Cell Growth Processes / physiology. Cell Line, Tumor. Coculture Techniques. Humans. Immunohistochemistry. Male. Receptor, Anaphylatoxin C5a. Receptors, Complement / metabolism. Statistics, Nonparametric. Tissue Array Analysis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20607747.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50-CA090386
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / C5AR1 protein, human; 0 / Receptor, Anaphylatoxin C5a; 0 / Receptors, Complement; 9035-58-9 / Thromboplastin
  •  go-up   go-down


42. Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih IeM, Roden RB: Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res; 2006 Apr 1;66(7):3754-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elevated levels of total ubiquitinated proteins and 19S and 20S proteasome subunits are evident in both low-grade and high-grade ovarian carcinoma tissues relative to benign ovarian tumors and in ovarian carcinoma cell lines relative to immortalized surface epithelium.
  • We find that ovarian carcinoma cell lines exhibit greater sensitivity to apoptosis in response to proteasome inhibitors than immortalized ovarian surface epithelial cells.
  • In sum, elevated proliferation and metabolic rate resulting from malignant transformation of the epithelium stresses the UPS and renders ovarian carcinoma more sensitive to apoptosis in response to proteasomal inhibition.
  • [MeSH-minor] Animals. Boronic Acids / pharmacology. Bortezomib. Caspases / metabolism. Cell Division / drug effects. Cell Line, Tumor. Female. G2 Phase / drug effects. Humans. Leupeptins / pharmacology. Mice. Mice, Nude. Oligopeptides / pharmacology. Pyrazines / pharmacology. Xenograft Model Antitumor Assays


43. Keylock JB, Galvin JR, Franks TJ: Sclerosing hemangioma of the lung. Arch Pathol Lab Med; 2009 May;133(5):820-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a brief review of sclerosing hemangioma, an uncommon but histologically distinctive neoplasm of the lung.
  • Based on immunohistochemical and molecular findings, sclerosing hemangioma is thought to be derived from incompletely differentiated respiratory epithelium.
  • Histologically, sclerosing hemangioma is characterized by a distinct constellation of findings including 2 epithelial cell types, surface cells and round cells, which form 4 architectural patterns, papillary, sclerotic, solid, and hemorrhagic.
  • Sclerosing hemangioma of the lung is generally considered to be a benign lesion, and surgical excision is curative without the need for additional treatment.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma / diagnosis. Carcinoma / secondary. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Male. Prognosis. Radiography, Thoracic. Respiratory Mucosa / metabolism. Respiratory Mucosa / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415961.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 29
  •  go-up   go-down


44. Temkin S, Nacharaju VL, Hellman M, Lee YC, Abulafia O: Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer. Steroids; 2006 Nov;71(11-12):1019-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of ovarian cancers are derived from ovarian surface epithelium and the inflammation caused by successive ovulation seems to a play a role in the development of cancer.
  • We undertook this study to investigate type 2 11beta-HSD activity which functions exclusively oxidative direction, in normal ovarian tissue compared to ovarian epithelial cancer.
  • Ovarian tissue was obtained from patients undergoing hysterectomy for both benign and malignant disease.
  • Decreased cortisol levels due type 2 1beta-HSD activity may play a role neoplastic transformation as well as tumor proliferation in ovarian cancer by eliminating anti-inflammatory action of cortisol.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17028049.001).
  • [ISSN] 0039-128X
  • [Journal-full-title] Steroids
  • [ISO-abbreviation] Steroids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.1.1.146 / 11-beta-Hydroxysteroid Dehydrogenase Type 2
  •  go-up   go-down


45. Fadare O, Liang SX, Ulukus EC, Chambers SK, Zheng W: Precursors of endometrial clear cell carcinoma. Am J Surg Pathol; 2006 Dec;30(12):1519-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recognition of morphologically identifiable lesions which may confer an increased risk for subsequent development of an invasive malignancy offers an opportunity to investigate and better understand the molecular-genetic etiopathogenesis of the well-developed tumor, and potentially, to administer a therapeutic intervention before its development.
  • Thirty-eight benign uteri and 30 uteri with classic endometrial endometrioid carcinoma (EEC) served as controls.
  • The lesions were typically isolated glands or surface epithelium (within an otherwise normal endometrial region) that displayed cytoplasmic clarity and/or eosinophilia with varying degrees of nuclear atypia.
  • In contrast, PPL were identified neither in the benign uteri nor in endometrioid carcinoma control groups (P<0.001).
  • The immunohistochemical expression of p53, mib-1, estrogen receptor (ERs), and progesterone receptor in the benign endometria, ECCC, and the PPL were evaluated on all 27 cases.
  • The mean p53 scores for the benign endometria, PPL, and ECCC were 0, 4.5, and 6.2, respectively.
  • ER/progesterone receptor indices for benign endometria, PPL, and carcinoma were 90/80, 21.52/4.61, and 11/4, respectively.
  • The PPL described herein have a morphologic and immunophenotypic profile which seems to be distinct from both the benign endometria in which they reside and the adjacent areas of ECCC.
  • The high frequency of association of these lesions with ECCC, their frequent occurrence as isolated lesions within otherwise "benign-appearing" endometria, and their continuous spectrum of nuclear atypia from minimum (grade 1, cytologic atypia falls short of ECCC cells) to maximum (grade 3, cytologically identical to ECCC cells), argues in favor of our hypothesis that these may represent precursor lesions of ECCC.
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Endometrium / chemistry. Endometrium / pathology. Exocrine Glands / chemistry. Exocrine Glands / pathology. Female. Humans. Immunoenzyme Techniques. Middle Aged. Single-Blind Method

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122507.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


46. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J: Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol; 2006 Sep;19(9):1149-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined IGFBP2 and IGFBP5 expression levels using two tissue microarrays, one containing six normal surface epithelium, six benign serous cysts, 10 serous borderline tumors, eight low-grade, and 20 high-grade serous carcinomas.
  • Each tumor was sampled in duplicate with a 1.0-mm punch core needle.
  • IGFBP2 and IGFBP5 were overexpressed in high-grade serous carcinomas compared to normal surface epithelium, benign serous cysts, serous borderline tumors, or low-grade serous carcinoma.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Image Processing, Computer-Assisted. Immunoenzyme Techniques. Neoplasm Staging. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 26 May 2006.
  • (PMID = 16729015.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 5
  •  go-up   go-down


47. Inaba K, Sakurai Y, Umeki Y, Kanaya S, Komori Y, Uyama I: Laparoscopic excision of subdiaphragmatic bronchogenic cyst occurring in the retroperitoneum: report of a case. Surg Laparosc Endosc Percutan Tech; 2010 Dec;20(6):e199-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although bronchogenic cysts (BCs) are benign congenital malformations usually occur in thoracic cavity, retroperitoneal location is extremely uncommon.
  • A 64-year-old Japanese woman was admitted to the hospital because of submucosal tumor in the upper part of the stomach.
  • An upper gastrointestinal endoscopy revealed a submucosal tumor located just distal to the esophagogastric junction.
  • The abdominal computed tomography scan revealed a cystic mass located in contact with lesser curvature of the stomach and the dorsal surface of the liver.
  • The cystic tumor was completely excised with a laparoscopic procedure.
  • The histologic findings indicated that the cyst was surfaced by the ciliated pseudostratified epithelium without the presence of the cartilage, which was compatible with the BC of the retroperitoneum.
  • [MeSH-minor] Endoscopy, Gastrointestinal. Endosonography. Epithelium / pathology. Female. Humans. Laparoscopy. Middle Aged. Retroperitoneal Space. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Bronchogenic Cyst.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150402.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Heye S, Bielen D, Vanbeckevoort D: Left ovarian Brenner tumor. JBR-BTR; 2005 Sep-Oct;88(5):245-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left ovarian Brenner tumor.
  • Nowadays there is general agreement that Brenner tumors are derived from the surface epithelium of the ovary or the pelvic mesothelium through transitional cell metaplasia.
  • Association with other surface-derived neoplasms, either in the ipsilateral or contralateral ovary, is reported in 30% of the cases.
  • We report a case of benign ovarian Brenner tumor and discuss the typical features on magnetic resonance imaging (MRI) and computed tomography (CT) scan as well as the differential diagnosis.
  • [MeSH-major] Brenner Tumor / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302335.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


49. Baba T, Kariya M, Higuchi T, Mandai M, Matsumura N, Kondoh E, Miyanishi M, Fukuhara K, Takakura K, Fujii S: Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition. Gynecol Oncol; 2007 Jun;105(3):703-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While there are some reports of NRP-1 expression in ovarian neoplasm, those results differ in pattern of its expression and its role in ovarian cancer is still unclear.
  • RESULTS: NRP-1 expression was found to be enhanced in ovarian cancer compared with ovarian surface epithelium (OSE), benign adenoma and tumors of low malignant potential.
  • [MeSH-minor] Cell Adhesion / physiology. Cell Count. Cell Growth Processes / physiology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. RNA, Small Interfering / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376520.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 144713-63-3 / Neuropilin-1
  •  go-up   go-down


53. Yoshida J, Horiuchi A, Kikuchi N, Hayashi A, Osada R, Ohira S, Shiozawa T, Konishi I: Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med Mol Morphol; 2009 Jun;42(2):82-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in the expression of E-cadherin have been reported to be important in the tumorigenesis and progression of epithelial ovarian carcinoma.
  • To further examine the mechanisms regulating E-cadherin expression in ovarian tumorigenesis, we investigated the immunohistochemical expression of transcriptional repressors for E-cadherin, such as Snail, Slug, SIP1, and Twist, in the ovarian surface epithelium (OSE) and 95 cases of epithelial ovarian tumors.
  • Of 95 ovarian tumors, the expression of Snail, Slug, SIP1, and Twist increased stepwise in benign, borderline, and malignant tumors.
  • Our results indicate that the expression of E-cadherin transcriptional repressors increased with malignancy in ovarian epithelial neoplasms and that the expression of E-cadherin and its negative regulators is altered during ovarian cancer development and peritoneal dissemination.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Blotting, Western. Disease Progression. Female. Humans. Immunohistochemistry. Nerve Tissue Proteins / analysis. Nerve Tissue Proteins / metabolism. Nuclear Proteins / analysis. Nuclear Proteins / metabolism. Ovary / chemistry. Ovary / cytology. Ovary / pathology. RNA-Binding Proteins / analysis. RNA-Binding Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Snail Family Transcription Factors. Twist-Related Protein 1 / analysis. Twist-Related Protein 1 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1437-47 [14507651.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):922-8 [9269828.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12 (18):5369-76 [17000670.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):24661-6 [11323412.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1469-76 [15619205.001]
  • [Cites] J Surg Res. 2007 Aug;141(2):196-203 [17583745.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):180-8 [10188716.001]
  • [Cites] J Pathol. 2000 Dec;192(4):460-9 [11113863.001]
  • [Cites] Br J Cancer. 2002 Jan 7;86(1):98-101 [11857019.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12 ):1816-22 [16773075.001]
  • [Cites] Lancet Oncol. 2006 Nov;7(11):925-34 [17081918.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3241-6 [12082640.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Mar;21(1):65-71 [12071532.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):155-65 [15790452.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):520-8 [17024425.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):314-20 [17211477.001]
  • [Cites] Clin Exp Metastasis. 2006;23(1):65-74 [16826427.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):155-66 [11994736.001]
  • [Cites] Biol Rev Camb Philos Soc. 1996 Nov;71(4):529-43 [8923798.001]
  • [Cites] J Pathol. 1998 Jul;185(3):262-6 [9771479.001]
  • [Cites] Histopathology. 1998 Jan;32(1):69-80 [9522220.001]
  • [Cites] Curr Opin Oncol. 1994 Jan;6(1):106-13 [7515692.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54 [10339573.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1756-9 [16880738.001]
  • [Cites] Clin Exp Metastasis. 2007;24(5):329-39 [17487558.001]
  • (PMID = 19536615.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / GEMIN2 protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / RNA-Binding Proteins; 0 / Repressor Proteins; 0 / SNAI1 protein, human; 0 / Snail Family Transcription Factors; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Twist-Related Protein 1
  •  go-up   go-down


54. Ritwik P, Brannon RB: Peripheral odontogenic fibroma: a clinicopathologic study of 151 cases and review of the literature with special emphasis on recurrence. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Sep;110(3):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The peripheral odontogenic fibroma (POdF) is a rare benign neoplasm of odontogenic origin with limited data on recurrence.
  • RESULTS: POdF should be considered a mixed odontogenic tumor because it is composed of active odontogenic epithelial and ectomesenchymal components.
  • Budding of the basal cell layer of the surface squamous epithelium was associated with higher recurrence (P=.0186); 27 cases with recurrence which exhibited this feature.
  • The presence of calcification in direct apposition to epithelial rests was associated with lower recurrence (P=.0076); 13 cases that did not recur exhibited this feature.
  • Budding of the surface epithelium and calcification in apposition to odontogenic epithelial rests are histologic predictors of recurrence.
  • [MeSH-major] Fibroma / pathology. Jaw Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Odontogenic Tumors / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Follow-Up Studies. Humans. Infant. Infant, Newborn. Logistic Models. Male. Middle Aged. Mixed Tumor, Malignant / pathology. Sex Distribution. Time Factors. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20674403.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


55. Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF: Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother; 2009 Sep;58(9):1375-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor cell expression of TLRs can promote inflammation and cell survival in the tumor microenvironment.
  • Here we sought to characterize the expression of TLRs in normal human ovaries, benign and malignant ovarian tumors from patients, and in established ovarian tumor cell lines.
  • We report that TLR2, TLR3, TLR4, and TLR5 are strongly expressed on the surface epithelium of normal ovaries.
  • TLR2, TLR3, TLR4, and TLR5 are expressed in benign conditions, epithelial tumors, and in ovarian cancer cell lines.
  • Variable expression of TLR6 and TLR8 was seen in benign and malignant epithelium of some patients, while expression of TLR1, TLR7, and TLR9 was weak.
  • These studies demonstrate expression of multiple TLRs in the epithelium of normal ovaries and in ovarian tumor cells, and may indicate a mechanism by which epithelial tumors manipulate inflammatory pathways to facilitate tumor progression.
  • [MeSH-minor] Adult. Aged. Animals. Epithelial Cells / metabolism. Estrous Cycle / metabolism. Female. Humans. Immunoenzyme Techniques. Mice. Mice, Inbred C57BL. Middle Aged. Prognosis. Tissue Array Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19184006.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Toll-Like Receptors
  •  go-up   go-down


56. Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N: HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod Sci; 2007 Sep;14(6):605-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
  • Interrelationships between HOXA7 expression and ovarian cancer progression are investigated by cDNA array and by immunohistochemistry of normal ovaries and 538 epithelial ovarian tumor microarrays.
  • HOXA7 mRNA expression was higher in carcinomas than in benign tumors.
  • HOXA7 protein was absent in normal surface epithelium but appeared in metaplastic regions.
  • There were significant associations of strong HOXA7 staining of stroma and tumor nuclei with the clear cell histotype (stroma: P = .0022, nuclei: P = .0003) and of weak/absent staining with serous carcinomas.
  • Tumor E-cadherin expression correlated significantly with HOX7 staining in stroma (P = .0002) but not within tumors.
  • HOXA7 staining of tumor cell nuclei is correlated significantly with improved disease-specific survival (P = .0104), which is suggestive of the biological and potentially clinical importance of subcellular HOXA7 localization.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cell Differentiation. Cystadenocarcinoma, Serous / chemistry. Homeodomain Proteins / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Cadherins / analysis. Cell Nucleus / chemistry. Cluster Analysis. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Stromal Cells / chemistry. Stromal Cells / pathology. Tissue Array Analysis


57. Ota T, Klausen C, Salamanca MC, Woo HL, Leung PC, Auersperg N: Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells. Differentiation; 2009 Feb;77(2):162-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells.
  • We studied the roles of three HOXA genes in cultured normal ovarian surface epithelial (OSE) cells and ovarian cancer cells.
  • They included HOXA4 and HOXA7 because, by cDNA microarray analysis, these were more highly expressed in invasive ovarian carcinomas than in benign or borderline (noninvasive) ovarian tumors, and HOXA9 because it characterizes normal oviductal epithelium, which resembles ovarian serous adenocarcinomas.
  • The expression of the HOXA genes varied among ovarian cancer cell lines, but was highest in lines with compact epithelial morphologies.
  • Thus, HOXA4 expression does not correlate with proliferation or with epithelial differentiation, but it increases in response to OSE cell dispersion and negatively regulates EGFR activation and the motility of OSE and of ovarian cancer cells.
  • HOXA4 expression was highest in cancer lines with compact epithelial growth patterns, suggesting, again, an anti-dispersion function.
  • In summary, increased HOXA4 expression in ovarian cancer appears to constitute a tumor-suppressive, homeostatic response to aberrant cell behavior, and, in particular, to cell dispersion and migration.
  • [MeSH-major] Epithelial Cells / metabolism. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Blotting, Western. Cell Differentiation. Cell Line, Tumor. Cells, Cultured. Down-Regulation. Female. Gene Expression Regulation. Humans. Middle Aged. Ovary / cytology. Ovary / metabolism. Reference Standards. Reverse Transcriptase Polymerase Chain Reaction


58. Kobayashi T, Shimura T, Araki K, Ogawa A, Mochida Y, Suzuki H, Suehiro T, Kuwano H: Lymphoepithelial cyst of the pancreas: report of a case. Hepatogastroenterology; 2008 May-Jun;55(84):1107-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 55-year-old man was incidentally diagnosed as having a pancreatic tumor by abdominal ultrasonography.
  • A hypoechoic cystic lesion was detected on the surface of the pancreatic body.
  • The lesion was diagnosed as a benign cystic tumor, and enucleation of the tumor was scheduled.
  • This cyst is an unusual but benign mass that requires minimal surgery.
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Epithelium / pathology. Humans. Laparoscopy. Lymphoid Tissue / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Pancreas / pathology. Pancreas / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705339.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


59. Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A: High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1529-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
  • The molecular etiology of epithelial ovarian cancer remains unclear.
  • Using microarray expression analysis, we recently reported that expression of the insulin-like growth factor binding protein-2 (IGFBP-2) gene is elevated in advanced epithelial ovarian cancers.
  • The aim of this study was to further delineate the role of IGFBP-2 in the pathoetiology of epithelial ovarian cancer and determine if elevated ovarian cancer IGFBP-2 gene expression is reflected in serum.
  • Relative IGFBP-2 expression was measured using quantitative real-time polymerase chain reaction in 113 epithelial ovarian cancers and 6 normal ovarian surface epithelial samples.
  • Preoperative serum IGFBP-2 levels were measured by radioimmunoassay in 84 women (42 ovarian cancers, 26 benign gynecological conditions, and 10 healthy female controls).
  • Ovarian cancers demonstrated 38-fold higher mean IGFBP-2 expression than normal ovarian epithelium (P < 0.01).
  • Serum IGFBP-2 levels were elevated in women with early- and advanced-stage ovarian cancer compared to controls and patients with benign gynecological conditions (P = 0.05 and P < 0.01, respectively).
  • Epithelial ovarian cancers express high levels of IGFBP-2 relative to normal ovarian epithelium, and this is associated with elevated serum IGFBP-2 levels compared to both normal controls and patients with benign gynecological disease.
  • Our findings provide further support that the insulin-like growth factor pathway plays a significant role in epithelial ovarian cancer pathogenesis.
  • Further, IGFBP-2 may represent an additional serum biomarker with utility in detection and monitoring of epithelial ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Gene Expression Regulation, Neoplastic / genetics. Insulin-Like Growth Factor Binding Protein 2 / blood. Neoplasms, Glandular and Epithelial / blood. Ovarian Neoplasms / blood. RNA, Messenger / blood
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / surgery. CA-125 Antigen / blood. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / blood. Endometrial Neoplasms / genetics. Endometrial Neoplasms / surgery. Female. Humans. Immunoenzyme Techniques. Neoplasm Staging. Ovarian Cysts / blood. Ovarian Cysts / genetics. Ovary / pathology. Precancerous Conditions / blood. Precancerous Conditions / genetics. Precancerous Conditions / surgery. Preoperative Care. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884361.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / RNA, Messenger
  •  go-up   go-down


60. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS: The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer; 2007 Apr 10;96(7):1083-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EphB4 expression was largely absent in normal ovarian surface epithelium, but was expressed in 86% of ovarian cancers.
  • We also studied the biological significance of EphB4 expression in ovarian tumour cells lines in vitro and in vivo.
  • All five malignant ovarian tumour cell lines tested expressed higher levels of EphB4 compared with the two benign cell lines.
  • Treatment of malignant, but not benign, ovarian tumour cell lines with progesterone, but not oestrogen, led to a 90% reduction in EphB4 levels that was associated with 50% reduction in cell survival.
  • Inhibition of EphB4 expression by specific siRNA or antisense oligonucleotides significantly inhibited tumour cell viability by inducing apoptosis via activation of caspase-8, and also inhibited tumour cell invasion and migration.
  • Furthermore, EphB4 antisense significantly inhibited growth of ovarian tumour xenografts and tumour microvasculature in vivo.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2001 Feb 15;230(2):139-50 [11161568.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):151-6 [17179984.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):220-6 [12562648.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):603-10 [12594815.001]
  • [Cites] Pathol Oncol Res. 2004;10(1):26-33 [15029258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5583-8 [15067119.001]
  • [Cites] Cell. 1998 May 29;93(5):741-53 [9630219.001]
  • [Cites] Virchows Arch. 1998 Aug;433(2):103-11 [9737787.001]
  • [Cites] Mol Cell. 1999 Sep;4(3):403-14 [10518221.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4623-32 [15930280.001]
  • [Cites] BMC Cancer. 2005;5:119 [16171530.001]
  • [Cites] Oncogene. 2006 Feb 2;25(5):769-80 [16205642.001]
  • [Cites] Panminerva Med. 2006 Mar;48(1):13-7 [16633327.001]
  • [Cites] Gynecol Oncol. 2006 Jul;102(1):15-21 [16499955.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):279-93 [16816380.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1236-48 [16615113.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):25-37 [11801721.001]
  • (PMID = 17353927.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / R01 CA079218; United States / NCI NIH HHS / CA / R01CA79218
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Progestins; 0 / RNA, Small Interfering; 4G7DS2Q64Y / Progesterone; EC 2.7.10.1 / Receptor, EphB4; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2360128
  •  go-up   go-down


61. Zhu Y, Brännström M, Janson PO, Sundfeldt K: Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer; 2006 Apr 15;118(8):1884-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours.
  • Human ovarian surface epithelium (OSE), regarded as the precursor cell of epithelial ovarian adenocarcinoma, is not a fully developed epithelium when situated on the ovarian surface.
  • It lacks epithelial characteristics such as the cell-cell adhesion factor epithelial (E)-cadherin, but as we have shown earlier, this OSE can form functional tight junctions (TJs) in culture.
  • Recent gene-expression data on ovarian adenocarcinoma has pointed out a family of TJ proteins, the claudins, to be highly expressed in malignant compared to benign ovarian tumours.
  • The purpose of this study was to investigate the distribution of claudin 1-5 proteins in cultured OSE (n=4), normal ovarian (n=11), benign (n=8), borderline (n=7) and ovarian cancer (n=22) tissues.
  • We found that a weak or absence of expression of claudin 3 and claudin 4 in surface OSE changed to typical cell-border localisation in OSE of inclusion cysts in the normal ovarian stroma.
  • Semiquantitative estimations of immunoblots showed that claudin 3 was significantly increased in ovarian adenocarcinomas compared to benign and borderline-type tumours.
  • Claudin 4 was significantly increased in both borderline-type and ovarian adenocarcinomas compared to benign tumours, whereas no changes were found for claudin 1 or 5.
  • The observations of lack of claudin 4 and low expression of claudin 3 in OSE strengthen our current knowledge about the biological nature of these cells as an undeveloped epithelium.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Claudin-1. Claudin-3. Claudin-4. Claudin-5. Epithelium. Female. Gene Expression Profiling. Humans. Immunoblotting. Ovary / physiology. Phenotype. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16287068.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudin-5; 0 / Membrane Proteins
  •  go-up   go-down


62. Guo J, Yang EC, Desouza L, Diehl G, Rodrigues MJ, Romaschin AD, Colgan TJ, Siu KW: A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma. Proteomics; 2005 May;5(7):1953-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma.
  • Surface-enhanced laser desorption/ionization-mass spectrometry (SELDI-MS) has conventionally been practiced on linear time of flight (TOF) which has low mass accuracy and resolution.
  • Immunohistochemical staining of a tissue microarray of 32 samples showed that approximately half of malignant endometrial tissues exhibited positive staining for calgranulin A in the malignant epithelium, while 9 out of 10 benign tissues exhibited negative epithelial staining.
  • [MeSH-major] Biomarkers, Tumor. Calgranulin A / metabolism. Chaperonin 10 / metabolism. Endometrial Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816004.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calgranulin A; 0 / Chaperonin 10
  •  go-up   go-down


63. Redjimi N, Gaudin F, Touboul C, Emilie D, Pallardy M, Biola-Vidamment A, Fernandez H, Prévot S, Balabanian K, Machelon V: Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer. Mol Cancer; 2009;8:83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer.
  • BACKGROUND: Little is known about the molecules that contribute to tumor progression of epithelial ovarian cancer (EOC), currently a leading cause of mortality from gynecological malignancies.
  • Glucocorticoid-Induced Leucine Zipper (GILZ), an intracellular protein widely expressed in immune tissues, has been reported in epithelial tissues and controls some of key signaling pathways involved in tumorigenesis.
  • The objectives of the current study were to examine the expression of GILZ in EOC and its effect on tumor cell proliferation.
  • RESULTS: GILZ expression was measured by immunohistochemical staining in tissue sections from 3 normal ovaries, 7 benign EOC and 50 invasive EOC.
  • GILZ was not detected on the surface epithelium of normal ovaries and benign tumors.
  • In contrast, it was expressed in the cytoplasm of tumor cells in 80% EOC specimens.
  • They were also higher in tumor cells containing large amounts of phosphorylated protein kinase B (p-AKT) (unpaired t test, P < 0.0001).
  • To assess the effect of GILZ on proliferation and AKT activation, we used the BG-1 cell line derived from ovarian tumor cells as a cellular model.
  • [MeSH-major] Epithelial Cells / pathology. Ovarian Neoplasms / pathology. Transcription Factors / metabolism


64. Aikhionbare FO, Mehrabi S, Kumaresan K, Zavareh M, Olatinwo M, Odunsi K, Partridge E: Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages. J Carcinog; 2007 Jan 26;6:1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages.
  • BACKGROUND: A majority of primary ovarian neoplasms arise from cell surface epithelium of the ovaries.
  • Although old age and a positive family history are associated risk factors, the etiology of the epithelial ovarian tumors is not completely understood.
  • Additionally, knowledge of factors involved in the histogenesis of the various subtypes of this tumor as well as those factors that promote progression to advanced stages of ovarian malignancy are largely unknown.
  • METHODS: In this study, we determined the presence of polymorphisms and other sequence variants of mitochondrial DNA (mtDNA) in 102 epithelial ovarian tumors including 10 matched normal tissues that paired with some of the tumors.
  • Furthermore, two mutations were observed in serous tumors only at np 1657 in stage IV (10/10), and at np 8221delA in benign cystadenomas (3/3) and borderline tumors (4/4).
  • A high frequency, 81% (13/16) of TC insertion at np 310 was found only in early stages of serous subtype (benign cystadenomas, 3/3; borderline tumors, 4/4; stage I tumors, 2/5 and matched normal tissues 4/4).
  • CONCLUSION: Our findings indicate that certain mtDNA mutations can reliably distinguish the different histologic subtypes of epithelial ovarian tumors.
  • In addition, these data raise the possibility that certain mtDNA mutations may be useful biomarkers for predicting tumor aggressiveness and may play a potential role in tumorigenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24 [15647368.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):291-3 [9806551.001]
  • [Cites] Biochim Biophys Acta. 1999 Feb 9;1410(2):103-23 [10076021.001]
  • [Cites] Eur J Cancer. 1999 Feb;35(2):316-9 [10448277.001]
  • [Cites] Mutat Res. 1999 Jul 30;434(3):177-203 [10486591.001]
  • [Cites] Science. 2000 Mar 17;287(5460):2017-9 [10720328.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4231-7 [10945635.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5007-11 [11016619.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1843-5 [11280735.001]
  • [Cites] Mutat Res. 2001 May;488(2):119-33 [11344040.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38555-62 [11504725.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5998-6001 [11507041.001]
  • [Cites] Am J Kidney Dis. 2001 Sep;38(3):529-36 [11532685.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7015-9 [11585726.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7623-6 [11606403.001]
  • [Cites] J Hum Genet. 2002;47(3):122-30 [11950064.001]
  • [Cites] Nucleic Acids Res. 2002 Jul 1;30(13):2817-24 [12087165.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2260-5 [12114429.001]
  • [Cites] J Pathol. 2003 Feb;199(2):237-42 [12533837.001]
  • [Cites] Cancer Lett. 2003 Feb 10;190(1):73-7 [12536079.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1838-43 [12578990.001]
  • [Cites] J Surg Oncol. 2003 Mar;82(3):170-3 [12619060.001]
  • [Cites] Hum Mutat. 2003 Apr;21(4):441-3 [12655558.001]
  • [Cites] Genetics. 1992 Jan;130(1):153-62 [1346260.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1314-20 [14647457.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):99-105 [14999140.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4466-77 [15016645.001]
  • [Cites] Mol Cancer Res. 2004 Aug;2(8):433-41 [15328370.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:30 [15482594.001]
  • [Cites] BMC Cancer. 2006;6:21 [16433919.001]
  • [Cites] Mutat Res. 2006 Mar 20;595(1-2):42-51 [16472830.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:259-66 [16515601.001]
  • [Cites] Hum Pathol. 1991 Aug;22(8):750-62 [1869263.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:208-18 [8747398.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):514-9 [9012815.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • (PMID = 17257433.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / P20 MD000272
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC1794240
  •  go-up   go-down






Advertisement